High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome

BACKGROUND: VEGF-targeted therapy has become the mainstay of treatment for majority of mRCC patients. For most patients, benefit is short-lived and therefore treatment remains palliative in intent. HD IL2 is an effective immunotherapy treatment capable of durable remission in some patients but its u...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, S., Galvis, V., Pillai, M., Leach, R., Keene, E., Spencer-Shaw, A., Shablak, A., Shanks, J., Liptrot, T., Thistlethwaite, F., Hawkins, R. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067981/
https://www.ncbi.nlm.nih.gov/pubmed/27777776
http://dx.doi.org/10.1186/s40425-016-0174-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5067981/
https://www.ncbi.nlm.nih.gov/pubmed/27777776
http://dx.doi.org/10.1186/s40425-016-0174-5

Ejemplares similares